Hyperfine Q2 Earnings Call Highlights

Revenue and system sales accelerated: Second-quarter revenue rose 45% year over year to $3.9 million, with 12 systems sold versus eight a year earlier. First-half revenue increased 62% to $7.8 million, while gross margin reached 50.7%. Model 2 adoption broadened: Most quarterly placements were next-generation Model 2 systems, spanning hospitals, neurology offices and international markets. Hyperfine also reported strong utilization and faster emergency-department scan times, with portable MRI reducing median order-to-scan-start time to 1.28 hours versus 7.76 hours for conventional MRI. Outlook and expansion plans were maintained: Hyperfine reiterated 2026 revenue guidance of $20 million to $22 million, gross margin of 50% to 55% and cash burn of $26 million to $28 million. The company is targeting an FDA submission for contrast-enhanced brain MRI labeling by the end of 2026 and expects its cash runway to extend into 2028.

Hyperfine reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, as the portable MRI company cited growth across hospital, neurology office and international markets. The company sold 12 systems during the quarter, compared with eight in the prior-year period. First-half revenue totaled $7.8 million, a 62% increase from $4.8 million a year earlier, while unit sales rose 57% to 22 systems. President and Chief Executive Officer Maria Sainz said the quarter was Hyperfine’s second-highest revenue quarter and marked its fourth consecutive quarter with gross margin above 50%.

Hyperfine said its next-generation Swoop portable MRI system, now called Model 2 and powered by Optive AI, continued to gain commercial traction. The company launched the system in mid-2025 and entered the neurology office market at that time. According to Sainz, most of the 12 systems placed in the second quarter were Model 2 systems, and international sales represented a high percentage of quarterly placements. The company said it is pursuing three principal commercial verticals: hospitals and health systems, neurology offices and international markets. In hospitals, Hyperfine said Model 2 deployments have moved beyond critical-care use into emergency departments, hospital-based clinics, neurological workflows and mobile deployment models. The company also reported sales to several new health systems, including an initial placement within one of the country’s largest national integrated delivery networks in early July. Sainz said hospitals that launched Model 2 programs in recent quarters have reported high utilization, increased scan volumes, and clinical workflow and economic benefits. Hyperfine expects these results to support additional deployments and more enterprise-level health system engagement over time. The company highlighted data from its PRIME study, presented at the Society for Academic Emergency Medicine’s 2026 meeting. Hyperfine said the data showed that portable MRI reduced the median time from order to scan start in emergency departments to 1.28 hours, compared with 7.76 hours for conventional MRI.

Hyperfine said it has placed Swoop systems in more than a dozen neurology offices since entering that market. Sainz said office staff have been able to operate the system without an MRI technologist, while several practices have reported high scan volumes. The company is seeing interest in dementia screening, concierge medicine and wellness practice mod...